デュシェンヌ型筋ジストロフィー（DMD）治療の世界市場 2020年

• 英文タイトル：Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：GIR201114245 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本書では、デュシェンヌ型筋ジストロフィー（DMD）治療の世界市場を調査対象にし、デュシェンヌ型筋ジストロフィー（DMD）治療の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（エテプリルセン51、デフラザコート、アタルレン）、用途別分析（病院、クリニック、在宅医療）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Sarepta Therapeutics、Bristol-Myers Squibb、PTC Therapeutics、Pfizer、Santhera Pharmaceuticals、Italfarmaco ・企業別売上、市場シェア ・デュシェンヌ型筋ジストロフィー（DMD）治療の地域別市場分析 ・デュシェンヌ型筋ジストロフィー（DMD）治療の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・デュシェンヌ型筋ジストロフィー（DMD）治療のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・デュシェンヌ型筋ジストロフィー（DMD）治療のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・デュシェンヌ型筋ジストロフィー（DMD）治療の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・デュシェンヌ型筋ジストロフィー（DMD）治療の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・デュシェンヌ型筋ジストロフィー（DMD）治療の種類別市場規模2015-2020：エテプリルセン51、デフラザコート、アタルレン ・デュシェンヌ型筋ジストロフィー（DMD）治療の用途別市場規模2015-2020：病院、クリニック、在宅医療 ・デュシェンヌ型筋ジストロフィー（DMD）治療の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論

Market Overview
The Duchenne Muscular Dystrophy (DMD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The most likely (base case) scenario is that the global Duchenne Muscular Dystrophy (DMD) Therapeutics sales will be xx in 2020 from Duchenne Muscular Dystrophy (DMD) Therapeutics million in 2019, with a change xx% between 2019 and 2020. In addition, based on the latest study, it is to predict that the Covid-19 will be under control in key countries like the United States, Western Europe, East Asia, by the end of Q2 (June), and will resume normal production in Q3 and Q4, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size is expected to grow at xx% or more annually for the next five years.

This report also researches and evaluates the impact of Covid-19 outbreak on the Duchenne Muscular Dystrophy (DMD) Therapeutics industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Duchenne Muscular Dystrophy (DMD) Therapeutics and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Market segmentation
Duchenne Muscular Dystrophy (DMD) Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Duchenne Muscular Dystrophy (DMD) Therapeutics market has been segmented into:
Exondys 51
Emflaza
Translarna

By Application, Duchenne Muscular Dystrophy (DMD) Therapeutics has been segmented into:
Hospitals
Clinics
Home Care

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Duchenne Muscular Dystrophy (DMD) Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Duchenne Muscular Dystrophy (DMD) Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy (DMD) Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Duchenne Muscular Dystrophy (DMD) Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Duchenne Muscular Dystrophy (DMD) Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Duchenne Muscular Dystrophy (DMD) Therapeutics are:
Sarepta Therapeutics
Bristol-Myers Squibb
PTC Therapeutics
Pfizer
Santhera Pharmaceuticals
Italfarmaco

レポート目次

---

1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics
1.2 Classification of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type in 2019
1.2.3 Exondys 51
1.2.4 Emflaza
1.2.5 Translarna
1.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
1.3.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Regions
1.4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Duchenne Muscular Dystrophy (DMD) Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Duchenne Muscular Dystrophy (DMD) Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Duchenne Muscular Dystrophy (DMD) Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Duchenne Muscular Dystrophy (DMD) Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Duchenne Muscular Dystrophy (DMD) Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Duchenne Muscular Dystrophy (DMD) Therapeutics Status and Prospect (2015-2025)
1.5 COVID-19 Outbreak: Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Impact
1.5.1 COVID-19 Potential Implications for the Duchenne Muscular Dystrophy (DMD) Therapeutics
1.5.1.1 Scenario One: Very Optimistic: COVID-19 has No Influence on Duchenne Muscular Dystrophy (DMD) Therapeutics
1.5.1.2 Scenario Two: Optimistic: COVID-19 Will Be Under Control by the End of April
1.5.1.3 Scenario Three: Gloomy: COVID-19 Will Be Under Control Between Q3 and Q4
1.5.1.4 Scenario Four: Most Likely: COVID-19 Will Be Under Control by the End of Q2
1.5.2 Opportunity Analysis in Covid-19 Crisis
1.5.3 Market Risk and Restraints
1.5.4 Market Driving Force
2 Company Profiles
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Sarepta Therapeutics SWOT Analysis
2.1.4 Sarepta Therapeutics Product and Services
2.1.5 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bristol-Myers Squibb SWOT Analysis
2.2.4 Bristol-Myers Squibb Product and Services
2.2.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 PTC Therapeutics
2.3.1 PTC Therapeutics Details
2.3.2 PTC Therapeutics Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 PTC Therapeutics SWOT Analysis
2.3.4 PTC Therapeutics Product and Services
2.3.5 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Santhera Pharmaceuticals
2.5.1 Santhera Pharmaceuticals Details
2.5.2 Santhera Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Santhera Pharmaceuticals SWOT Analysis
2.5.4 Santhera Pharmaceuticals Product and Services
2.5.5 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Italfarmaco
2.6.1 Italfarmaco Details
2.6.2 Italfarmaco Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Italfarmaco SWOT Analysis
2.6.4 Italfarmaco Product and Services
2.6.5 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share
3.2.2 Top 10 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Regions
4.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries
5.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
5.2 USA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries
6.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
7.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries
8.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Duchenne Muscular Dystrophy (DMD) Therapeutics by Countries
9.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Type (2019-2024)
10.3 Exondys 51 Revenue Growth Rate (2015-2025)
10.4 Emflaza Revenue Growth Rate (2015-2025)
10.5 Translarna Revenue Growth Rate (2015-2025)
11 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Segment by Application
11.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Home Care Revenue Growth (2015-2020)
12 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2021-2025)
12.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Forecast (2021-2025)
12.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Estimation in Various Scenarios in 2020
Table 6. Sarepta Therapeutics Corporate Information, Location and Competitors
Table 7. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Major Business
Table 8. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 9. Sarepta Therapeutics SWOT Analysis
Table 10. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 11. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 12. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 13. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Major Business
Table 14. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Total Revenue (USD Million) (2018-2019)
Table 15. Bristol-Myers Squibb SWOT Analysis
Table 16. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 17. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 18. PTC Therapeutics Corporate Information, Location and Competitors
Table 19. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Major Business
Table 20. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 21. PTC Therapeutics SWOT Analysis
Table 22. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 23. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 24. Pfizer Corporate Information, Location and Competitors
Table 25. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Major Business
Table 26. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 27. Pfizer SWOT Analysis
Table 28. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 29. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 30. Santhera Pharmaceuticals Corporate Information, Location and Competitors
Table 31. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Major Business
Table 32. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 33. Santhera Pharmaceuticals SWOT Analysis
Table 34. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 35. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 36. Italfarmaco Corporate Information, Location and Competitors
Table 37. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Major Business
Table 38. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Total Revenue (USD Million) (2017-2018)
Table 39. Italfarmaco SWOT Analysis
Table 40. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 41. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 42. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 43. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players (2015-2020)
Table 44. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 45. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Regions (2015-2020)
Table 46. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
Table 47. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 48. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 49. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 50. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Countries (2015-2020)
Table 51. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 52. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 53. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Table 54. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 55. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2015-2020)
Table 56. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Type (2021-2025)
Table 57. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue by Application (2015-2020)
Table 58. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2015-2020)
Table 59. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Application (2021-2025)
Table 60. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Type in 2019
Figure 3. Exondys 51 Picture
Figure 4. Emflaza Picture
Figure 5. Translarna Picture
Figure 6. Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Application in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Home Care Picture
Figure 10. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share in 2019
Figure 19. Global Top 10 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 23. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Regions in 2018
Figure 24. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 30. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries in 2019
Figure 31. USA Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries in 2019
Figure 36. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. UK Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. France Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries in 2019
Figure 43. China Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. India Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries in 2019
Figure 50. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type (2015-2020)
Figure 59. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Type in 2019
Figure 60. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Type (2021-2025)
Figure 61. Global Exondys 51 Revenue Growth Rate (2015-2020)
Figure 62. Global Emflaza Revenue Growth Rate (2015-2020)
Figure 63. Global Translarna Revenue Growth Rate (2015-2020)
Figure 64. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application (2015-2020)
Figure 65. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Application in 2019
Figure 66. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Application (2021-2025)
Figure 67. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 68. Global Clinics Revenue Growth Rate (2015-2020)
Figure 69. Global Home Care Revenue Growth Rate (2015-2020)
Figure 70. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel

---